TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00597389

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inderol (propranolol)
Description: Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inderol (propranolol)
Description: Children ingested a propranolol HCL 20 mg/5 ml solution twice daily for 10 days (and taper for 5 days). Medication was initiated within 12 hours post-trauma. Dose was calculated to be 2.5 mg/kg/d with a maximum dose of 40 mg.
Study: NCT03973398

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum block
Description: ultrasound guided Quadratus Lumborum block for postoperative pain

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus Lumborum block
Description: ultrasound guided Quadratus Lumborum block for postoperative pain

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus Lumborum block
Description: ultrasound guided Quadratus Lumborum block for postoperative pain

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Quadratus Lumborum block
Description: ultrasound guided Quadratus Lumborum block for postoperative pain
Study: NCT03864523

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Study: NCT04671394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: FMUD + DLIG
Description: Full-Mouth Ultrasonic Debridement + Diode Laser and Indocyanine Green solution

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: FMUD + ST
Description: Full-Mouth Ultrasonic Debridement + Sham Treatment
Study: NCT03727841

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Marizomib
Description: 0.8mg/m(2) intravenous (IV) on days 1, 8, and 15 of each 28-day cycle, 24 cycles total.
Study: NCT01761929

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: 50Gy in 5 fr (max) to 25 Gy in 5 fr (min). Dose adapted to deliver the highest dose level while respecting normal tissue tolerance
Description: All patients will be treated with SBRT 1-2 weeks after radiotherapy planning scans. Therapy will be given once daily, over 5 consecutive working days according to standard practice.
Study: NCT00519584

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: 30 ml 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine
Description: 30 ml 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dex
Description: 8 mg (2 ml)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dex
Description: 8 mg (2 ml)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine
Description: 30 ml 0.5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: 30 ml 0.5%

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% saline; systemic and local

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.9% saline; systemic and local
Study: NCT02728284

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: cardiovascular MRI (CMR)
Description: CMR is used to demonstrate cardiac abnormalities and assess cardiac function in many patients

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Cardiologic Evaluation
Description: ECG (gating), and respiratory motion effects
Study: NCT01400724

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Inofolic NRT
Description: Dietary supplement: myo-inositol 2000 mg plus cocoa polyphenols 30 mg and plus isoflavones 80 mg
Study: NCT03061188

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study: NCT02728076

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phase II - Preoperative Radiation followed by Lumpectomy.
Description: Selected patients will undergo a radiation planning procedure utilizing magnetic resonance imaging (MRI). Once this is completed, patients will receive five radiation treatments given every other day. After 28 days (four weeks), patients will have another MRI scan to compare tumor response to the radiation therapy. Following the MRI scan, roughly five to eight weeks later, patients will have a lumpectomy and possibly a sentinel lymph node biopsy. After surgery, tests will be performed on the tumor tissue to determine if genes expressed in the sample have changed. Following surgery, patients will receive chemotherapy and/or antihormone therapy at the discretion of the patient and physician.
Study: NCT03816358

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anetumab Ravtansine
Description: Given IV

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV
Study: NCT03061188

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study: NCT04351880

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medically Tailored Meals
Description: Compare 2 and 4 weeks of meal delivery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Medically Tailored Meals
Description: Compare 2 and 4 weeks of meal delivery
Study: NCT01541072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim
Description: Pegfilgrastim (Neulasta®, AMGEN Laboratories): single subcutaneous administration of Pegfilgrastim, 6 mg at day 5 (D5) after autologous stem cell transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Filgrastim
Description: Filgrastim (Neupogen®, AMGEN Laboratories): daily subcutaneous administration, 5µg/kg/day from day 5 (D5) after autologous stem cell transplantation until recovery from aplasia (Neutrophils \>= 0.5 G/L)
Study: NCT02091401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Springfusor infusion pump

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IV administration

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Study: NCT01509612

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Additive classical homeopathy
Description: Homeopathic remedies every 2 to 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Homeopathic Placebo globules
Description: Homeopathic placebo globules every 2 to 3 months
Study: NCT01940640

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA
Description: We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA (900 mg/day) during the lactation (minimum period of 3 months).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: control
Description: We will establish two groups of premature newborn children (\<34 weeks) (n=40) and one group of newborn children to term (n=40). The mothers of one of the groups of premature newborn children will receive an oral supplementation by means of capsules with high dose of DHA during the lactation (minimum period of 3 months).
Study: NCT02587195

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teriflunomide
Study: NCT02895191

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: Patients will receive the study drugs for 7 to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: Patients will receive the study drugs for 7 to 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ulinastatin
Description: Patients will receive the study drugs for 7 to 14 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Patients will receive the placebo for 7 to 14 days
Study: NCT02595385

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell Salvage
Description: Reinfusion of shed blood during the operation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cell Salvage
Description: Reinfusion of shed blood during the operation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Autologous Prime
Description: Removal of fluid from the bypass circuit

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Retrograde Autologous Prime
Description: Removal of fluid from the bypass circuit
Study: NCT03915483

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial direct current stimulation (tDCS)
Description: sham or real tDCS for 10 minutes of 1.5 milliampere (mA) tDCS targeting the prefrontal and the posterior parietal cortex

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation (tDCS)
Description: sham or real tDCS for 10 minutes of 1.5 milliampere (mA) tDCS targeting the prefrontal and the posterior parietal cortex
Study: NCT03141515

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lung ultrasound
Description: Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lung ultrasound
Description: Lung ultrasound examination at two different times-point immediately after induction and after recruitment maneuver to monitor lung aeration.
Study: NCT01758614

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bypass surgery
Description: all participants in this group will be performed EC-IC bypass surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: all participants in this group will be given medical therapy including Aspirin 100mg per day or clopidogrel 75mg per day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Study: NCT02378974

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cordstem-ST

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Cordstem-ST

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Placebo
Study: NCT04397549

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cervical erector spinae plane block
Description: Cervical erector spinae plane block will be administered before the surgery

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Intravenous morphine patient controlled analgesia device
Description: 24 hour morphine consumption will be recorded
Study: NCT03474445

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar Plate Osteosynthesis Aptus 2.5
Description: Volar plating of distal radius fracture. Device: Aptus 2.5

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Volar Plate Osteosynthesis Inteos 2.5
Description: Volar plating of distal radius fracture. Device: Inteos 2.5
Study: NCT00973284

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk VLP vaccine
Description: Norwalk VLP vaccine dry powder

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: mannitol and sucrose
Description: Mannitol and sucrose as placebo-matching Norwalk VLP Vaccine dry powder

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Norwalk virus
Description: Norwalk virus solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Norwalk virus
Description: Norwalk virus solution
Study: NCT03569826

Intervention type: OTHER
Intervention: Observational; no intervention
Description: Observational; no intervention
Study: NCT04204304

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Isotretinoin
Description: ISO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Isotretinoin
Description: ISO
Study: NCT00299403

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Right prefrontal lowfrequency ( 1 hz) rTMS.
Description: Right prefrontal low frequency (1 hz) rTMS. 15 sessions with one daily session during 3 weeks (weekends excluded). Each session covering 2 x 60 minutes of stimulation separated with an intertrain interval of 3 minutes~Arms: 2

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Description: 9 ECT ( 3 each week) during 3 weeks
Study: NCT02334345

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evoskin
Description: Evoskin is Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trixiera
Description: Trixiera is a topical agent recommended to help patients in the management of radiation skin reactions
Study: NCT03023267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Music therapy and Kangaroo care
Description: Mother holding baby in skin to skin position while singing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Kangaroo Care alone
Description: Mother holding baby in skin to skin position without singing
Study: NCT02595112

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Staphylococcus aureus carriage
Description: Vestibulum nasi and posterior nasal cavity sampling with swabs and posterior nasal cavity sampling by endoscopic procedure during otorhinolaryngologic surgery
Study: NCT01223937

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00835835

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Body-weight supported treadmill training +/- Lokomat assistance
Description: walking

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care - no active intervention
Description: No treatment used for comparison
Study: NCT01027377

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFVIIIFc
Description: Single dose
Study: NCT04504565

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 99mTc-3PRGD2
Description: intravenous injection of 0.3 mCi/kg of 99mTc-3PRGD2
Study: NCT03360214

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine Hydrochloride
Description: For active drug, 0.25% marcaine, will be used.

Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine Hydrochloride
Description: For active drug, 0.25% marcaine, will be used.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Drug
Description: For sham drug, 0.9% saline, will be used.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Drug
Description: For sham drug, 0.9% saline, will be used.

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed Electromagnetic Field (PEMF) Device
Description: The pulsed electromagnetic field signal will consist of a 2-m sec burst of 27.12 megahertz (MHz) radiofrequency sinusoidal waves repeating at 2 bursts/second.

Intervention type: DEVICE
Group type: OTHER
Intervention: Pulsed Electromagnetic Field (PEMF) Device
Description: The pulsed electromagnetic field signal will consist of a 2-m sec burst of 27.12 megahertz (MHz) radiofrequency sinusoidal waves repeating at 2 bursts/second.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Device
Description: Sham devices will appear identical to and will be used in exactly the same manner as active devices but will produce no electromagnetic field.

Intervention type: OTHER
Group type: OTHER
Intervention: Placebo Device
Description: Sham devices will appear identical to and will be used in exactly the same manner as active devices but will produce no electromagnetic field.

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine Hydrochloride
Description: For active drug, 0.25% naropin, will be used.

Intervention type: DRUG
Group type: OTHER
Intervention: Ropivacaine Hydrochloride
Description: For active drug, 0.25% naropin, will be used.
Study: NCT00110357

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + Irinotecan
Description: Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 16 or 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab + Irinotecan
Description: Intravenous (IV) cetuximab 75 - 250 mg/m2 depending on dose escalation for MTD, weekly; irinotecan was administered at a dose of 20 mg/m2 or per dose escalation, administered x5 days x2 weeks, separated by 2 days off, every 21 days.
Study: NCT01748019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ST1968
Description: ST1968 once a week for 2 weeks every 3 weeks (protocol amendment: once every 3 weeks
Study: NCT00060606

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Prenatal Myelomeningocele Repair Surgery
Description: Fetal surgery to repair spina bifida defect performed prior to 26 weeks of gestation with delivery by C-section at approximately 37 weeks of gestation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Postnatal Myelomeningocele Repair Surgery
Description: Standard postnatal surgical closure of the spina bifida defect
Study: NCT03739424

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole egg powder
Description: Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole egg powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole milk powder
Description: Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with whole milk powder. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Gelatin food product
Description: Participants will receive waffles, pancakes, brownies, ice cream and mac and cheese made with gelatin. The food projects were developed specifically for this study by the University of Georgia's Food Product Innovation and Commercialization Center and consumer tested by children within the study age range prior to intervention enrollment.
Study: NCT01960166

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Active Distraction
Description: iPad will be used as active distraction

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Passive Distraction
Description: child will watch TV as passive distraction
Study: NCT02017093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Error Enhancement
Description: Patients underwent upper extremity robotic training with the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: control treatment
Description: Patients underwent upper extremity robotic training without the error enhancement effect. Training have focused on hand reaching movements in varity of directions and range of motions.
Study: NCT03155347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tocilizumab
Description: Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive tocilizumab 162 mg given as 0.9 milliliter (mL) of a 180 mg/mL solution in a prefilled syringe, administered by SC injection Q2W.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MTX
Description: Participants will receive MTX stable doses at 10 to 25 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Participants will receive MTX stable doses at 10 to 25 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MTX
Description: Participants will receive MTX stable doses at 10 to 25 mg orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo Matched to MTX
Description: Placebo matched to MTX.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Matched to Tocilizumab
Description: Placebo matched to tocilizumab.
Study: NCT02837302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Livact
Description: Daily dose of 12.45g of branched-chain amino acid containing 3.4g of L-valine, 5.7g of L-leucine, and 2.9g of L-isoleucine over 6 months.